Histone deacetylase inhibitors in the therapy of cancer: Much to learn

Epigenomics

Volumn 2, Issue 6, 2010, Pages 723-725

  Lee, Ju Hee ^a   Marks, Paul A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

DNA double strand breaks; HDAC6 specific inhibitor; histone deacetylase; histone deacetylase inhibitor

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; VORINOSTAT;

CANCER THERAPY; CELL CYCLE ARREST; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN STRUCTURE; DNA SEQUENCE; DOUBLE STRANDED DNA BREAK; EDITORIAL; EPIGENETICS; GENE EXPRESSION; PRIORITY JOURNAL;

CELL DEATH; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; LYSINE; NEOPLASMS;

EID: 78650441344     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.10.59     Document Type: Editorial

References (23)

1. Liutkeviciute Z, Lukinavicius G, Masevicius V, Daujotyte D, Klimasauskas S: Cytosine-5-methyltransferases add aldehydes to DNA. Nat. Chem. Biol. 5, 400-402 (2009)
2. Marks PA: Histone deacetylaseinhibitors: a chemical genetics approach to understanding cellular functions. Biochim. Biophys. Acta DOI: 10.1016/j. bbagrm.2010.05.008 (2010) (Epub ahead of print).
3. Schrump DS: Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin. Cancer Res. 15(12), 3947-3957 (2009).
4. Tan J, Cang S, Ma Y, Petrillo RL, Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol. 3, 5 (2010).
5. Willyard C: The saving switch. Nat. Med. 16(1), 18-21 (2010).
6. Marks PA: The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin. Investig. Drugs 19(9), 1049-1066 (2010).
7. Shahbazian MD, Grunstein M: Functions of site-specific histone acetylation and deacetylation. Annu. Rev. Biochem. 76, 75-100 (2007).
8. Struhl K: Gene regulation. A paradigm for precision. Science 293(5532), 1054-1055 (2001).
9. Jones PA, Baylin SB: The epigenomics of cancer. Cell 128(4), 683-692 (2007).
10. Gregoretti IV, Lee YM, Goodson HV: Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 338(1), 17-31 (2004).
11. Choudhary C, Kumar C, Gnad F et al.: Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325(5942), 834-840 (2009).
12. Esteller M: Epigenetics in cancer. N. Engl. J. Med. 358(11), 1148-1159 (2008).
13. Parmigiani RB, Xu WS, Venta-Perez G et al.: HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc. Natl Acad. Sci. USA 105(28), 9633-9638 (2008).
14. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL: Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl Acad. Sci. USA 100(8), 4389-4394 (2003).
15. Zhang X, Yuan Z, Zhang Y et al.: HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol. Cell 27(2), 197-213 (2007).
16. Kovacs JJ, Murphy PJ, Gaillard S et al.: HDAC6 regulates HSP90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18(5), 601-607 (2005).
17. Kawaguchi Y, Kovacs JJ, Mclaurin A, Vance JM, Ito A, Yao TP: The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115(6), 727-738 (2003).
18. Finnin MS, Donigian JR, Cohen A et al.: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401(6749), 188-193 (1999).
19. Ficner R: Novel structural insights into class I and II histone deacetylases. Curr. Top. Med. Chem. 9(3), 235-240 (2009).
20. Lee JH, Choy ML, Ngo L, Foster SS, Marks PA: Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc. Natl Acad. Sci. USA 107(33), 14639-14644 (2010).
21. Ungerstedt JS, Sowa Y, Xu WS et al.: Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102(3), 673-678 (2005).
22. Kato T, Shimono Y, Hasegawa M et al.: Characterization of the HDAC1 complex that regulates the sensitivity of cancer cells to oxidative stress. Cancer Res. 69(8), 3597-3604 (2009).
23. Tan J, Zhuang L, Jiang X, Yang KK, Karuturi KM, Yu Q: Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity. J. Biol. Chem. 281(15), 10508-10515 (2006).